Precigen’s (PGEN) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reissued their buy rating on shares of Precigen (NASDAQ:PGEN) in a report published on Thursday,Benzinga reports. The brokerage currently has a $6.00 price objective on the biotechnology company’s stock, up from their previous price objective of $4.00.

Separately, JMP Securities reissued a “market outperform” rating and set a $5.00 price objective on shares of Precigen in a research report on Tuesday, January 14th. Two research analysts have rated the stock with a sell rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $7.00.

Precigen Trading Up 18.6 %

Shares of PGEN stock opened at $1.34 on Thursday. The business’s 50 day moving average price is $0.93 and its 200-day moving average price is $1.06. Precigen has a fifty-two week low of $0.65 and a fifty-two week high of $1.93.

Institutional Investors Weigh In On Precigen

Several hedge funds have recently made changes to their positions in the company. Iridian Asset Management LLC CT lifted its position in Precigen by 82.5% during the third quarter. Iridian Asset Management LLC CT now owns 3,775,960 shares of the biotechnology company’s stock valued at $3,576,000 after buying an additional 1,706,815 shares during the period. Geode Capital Management LLC increased its stake in shares of Precigen by 4.8% in the 3rd quarter. Geode Capital Management LLC now owns 3,246,508 shares of the biotechnology company’s stock worth $3,075,000 after acquiring an additional 149,829 shares in the last quarter. State Street Corp lifted its position in Precigen by 1.0% during the 3rd quarter. State Street Corp now owns 2,872,064 shares of the biotechnology company’s stock valued at $2,720,000 after acquiring an additional 29,253 shares during the period. Charles Schwab Investment Management Inc. boosted its stake in Precigen by 11.6% during the third quarter. Charles Schwab Investment Management Inc. now owns 1,222,850 shares of the biotechnology company’s stock worth $1,158,000 after acquiring an additional 127,467 shares in the last quarter. Finally, Renaissance Technologies LLC grew its holdings in Precigen by 12.4% in the second quarter. Renaissance Technologies LLC now owns 1,182,690 shares of the biotechnology company’s stock worth $1,869,000 after purchasing an additional 130,500 shares during the period. 33.51% of the stock is currently owned by institutional investors.

About Precigen

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.